HBK Sorce Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
HBK Sorce Advisory's VRTX Position: Q2 2026 in Review
HBK Sorce Advisory increased its Vertex Pharmaceuticals (VRTX) stake by 3.9% in Q2 2026, buying an estimated $15.1K and bringing the position to 916 shares worth $444K. The position accounts for 0.01% of the portfolio, ranked #403.
HBK Sorce Advisory first reported a position in VRTX in Q2 2024 and has held it in 9 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- HBK Sorce Advisory held 916 shares of Vertex Pharmaceuticals worth $444K as of Q2 2026.
- HBK Sorce Advisory bought 34 Vertex Pharmaceuticals shares in Q2 2026, an estimated $15.1K.
- Vertex Pharmaceuticals made up 0.01% of HBK Sorce Advisory's portfolio in Q2 2026, its #403 holding.
- HBK Sorce Advisory first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
- 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on HBK Sorce Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.